Summary of the interim report
First Half Year (1 January to
· Operating revenue KSEK 0 (0)
· Income after financial items KSEK -24 370 (-13 412)
· Earnings per share -0,50 (-0,36)
· Cash and cash equivalents as of
· Equity ratio as of
Second quarter (1 April to
· Operating revenue KSEK 0 (0)
· Income after financial items KSEK -14 187 (-6 655)
· Earnings per share -0,29 (-0,18)
Significant events during the second quarter of 2020
· Dr
·
· Cyxoned entered a development agreement with inventor
Significant events after the end of the period
·
·
·
CEO
It has been an exciting and productive three months since I started as CEO and I am happy to present my first interim report for
Since I joined the company the team has worked diligently to meet several important milestones. Signing the development agreement with
Last week we also had the pleasure to announce that Christin Arrhenius Bokedal will join
Development projects
The development of our drug projects - T20K for MS and Rabeximod for RA - are progressing according to plan. The Rabeximod tox results that I know many have been waiting for are also on time, and as we have communicated earlier there is now an extensive work to be done to properly analyse all the data generated from the study. Treating the animals for 6 months has generated data, and now the work to analyse and report the data will take the usual time for this type of study. We will communicate the results as soon as the study report has been finalized.
Preclinical studies on T20K are moving forward as planned. Recent studies show that the drug is highly stable in the gastro-intestinal tract, which is an important feature for oral administration of a peptide drug. Further nonclinical and formulation studies are ongoing.
Follow our news and information about our presence at investment events via Nasdaq First North and our website at: www.cyxone.com.
CEO,
Upcoming financial reports
November 13th, 2020 Interim Report Q3
February 12th, 2021 Year-end Report 2020
Submission of interim report
Malmö
The Board of Directors
Disclaimer
This is a translation of the original Swedish version of the interim report. In case of any discrepancy between this translation and the Swedish original, the latter shall prevail.
Contact
Phone: +46 (0) 70 781 88 08
Email: tara.heitner@cyxone.com
Adelgatan 21
211 22 Malmö,
This report contains such information that
This report contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this report.
About
https://news.cision.com/cyxone/r/interim-report-1-january-to-30-june-2020,c3182940
https://mb.cision.com/Main/16882/3182940/1298824.pdf
(c) 2020 Cision. All rights reserved., source